(Q47805253)

5 February 2018

title

A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major (English)

1 reference

5 February 2018

1 reference

5

Koussay Dellagi

1 reference

5 February 2018

author name string

Sami Ben Hadj Ahmed

1

1 reference

5 February 2018

Chokri Bahloul

2

1 reference

5 February 2018

Cyrine Robbana

3

1 reference

5 February 2018

Souhir Askri

4

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 April 2004

1 reference

5 February 2018

published in

Vaccine

1 reference

5 February 2018

volume

22

1 reference

5 February 2018

issue

13-14

1 reference

5 February 2018

page(s)

1631-1639

1 reference

5 February 2018

Clinical spectrum of Leishmaniasis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

The immunology of susceptibility and resistance to Leishmania major in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Genetic immunization is a simple method for eliciting an immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Salvation in a snippet of DNA?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Genetic vaccination against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Therapy of murine cutaneous leishmaniasis by DNA vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Expression cloning of a protective Leishmania antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Resistance to Leishmania major induced by tolerance to a single antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

IL-4 Rapidly Produced by Vβ4 Vα8 CD4+ T Cells Instructs Th2 Development and Susceptibility to Leishmania major in BALB/c Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Susceptibility to infectious diseases: Leishmania as a paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.10.046

10.1016/J.VACCINE.2003.10.046

7 January 2021

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018